The opioids market growth continues to demonstrate resilience as the pharmaceutical industry invests in next-generation opioid molecules designed to provide analgesia with reduced liability for respiratory depression, tolerance, and dependence. Novel G protein-biased agonists, peripherally restricted opioids, and mixed opioid receptor modulators represent promising therapeutic approaches that...